Sanofi EPS soars 47% to €1.82 in Q3

Wednesday, 31. October 2018 07:34

Sanofi S.A. reported on Wednesday that its earnings per share (EPS) for the third quarter of 2018 stood at €1.82, soaring 46.8% from the same period last year. The French pharmaceutical giant said its net sales in the three-month period amounted to €9.4 billion, improving 3.7% year on year.

Net income stood at €2.3 billion, surging 45.7% from the same quarter last year. Business net income rose 7.6%% to €2.3 billion compared to the same three months in 2017, while its business EPS increased 8.2% to €1.84 in the same period.

"In the third quarter, Sanofi entered a new growth phase. We delivered strong results with double-digit growth in Specialty Care and Emerging Markets, while Vaccines contributed a high-single digit increase in sales. In addition, we are looking forward to expanding our Specialty Care business with the launches of Libtayo, Cablivi and Dupixent for asthma. Based on the underlying dynamics demonstrated in the quarter, Sanofi is now well positioned to deliver growth," CEO Olivier Brandicourt stated.

Related Links: Sanofi S.A.Sanofi S.A.
Breaking the News / NP